

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

June 23, 2015

<u>Via E-mail</u> Mark Fletcher Chief Executive Officer Generex Biotechnology Corp. 555 Richmond Street West, Suite 604 Toronto, Ontario M5V 3B1

> Re: Generex Biotechnology Corp. Preliminary Proxy Statement on Schedule 14A Filed on June 2, 2015 File No. 000-25169

Dear Mr. Fletcher:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler Assistant Director

cc: <u>Via E-mail</u> Gary Miller, Esq. Eckert Seamans Cherin & Mellott, LLC